Immunotherapy has shown clinical benefit in various cancers, but only a minority of patients respond to it. Here, the authors investigate mechanisms of sensitivity to anti-PD-L1 immune checkpoint inh…
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to myelodysplastic syndromes.
The FORTIFI-HN01 trial has begun enrolling patients with advanced head and neck cancer to evaluate ficerafusp alfa plus pembrolizumab as a first-line therapy.
CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.
Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.
Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.
New research suggests that firstborn twins may have a greater risk of developing leukemia than second-born twins.
A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA…
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Directly measuring gene transcription activity from DNA reveals that hyper-elevated RNA Polymerase II levels are associated with tumor aggressiveness.
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.
